Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer Academic Article uri icon

Overview

MeSH Major

  • Breast Neoplasms
  • DNA Mutational Analysis
  • Drug Resistance, Neoplasm

abstract

  • Mutational burden in heavily treated trastuzumab-resistant Her2-positive metastatic breast cancer is highly variable and not directly correlated with outcome. Activation of the MAPK/ERK pathway through mutations in EGFR, BRAF or KIT may mediate resistance to trastuzumab.

publication date

  • February 28, 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5486569

Digital Object Identifier (DOI)

  • 10.1007/s00432-017-2358-x

PubMed ID

  • 28247034

Additional Document Info

start page

  • 1

end page

  • 8